Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.83 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082359 | 0.97 | PARP1 (0.85) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3072832 | 0.91 | PARP1 (1.00) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3066732 | 0.90 | PARP1 (0.98) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3061740 | 0.88 | PARP1 (1.00) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3067627 | 0.87 | PARP1 (0.98) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3066203 | 0.82 | PARP1 (1.00) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3085637 | 0.82 | PARP1 (0.81) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL29223126 | 0.81 | PARP1 (0.73) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL29223266 | 0.81 | PARP1 (0.73) | PARP1CHEK1MAP2K1GAAALDH1A1 | |
| SCHEMBL3086535 | 0.80 | PARP1 (0.78) | PARP1CHEK1MAP2K1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114948-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-7790721-B2 | Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885CHEK1 311/4885MAP2K1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.